VenatoRx Appoints Dr. Michael Diem To The Board Of Directors

VenatoRx Appoints Dr. Michael Diem To The Board Of Directors

Malvern, PA, September 12, 2016 — VenatoRx Pharmaceuticals today announced the appointment of Dr. Michael Diem to the VenatoRx Board of Directors. Dr. Diem is Senior Vice President, Business and Corporate Development at Medgenics, heading all business and corporate development activities for the company. Mike was recently with AstraZeneca as the Head of Corporate Strategy and Corporate Development, where he was responsible globally for corporate strategy, corporate development and MedImmune Ventures. Prior to joining AstraZeneca, Mike was the Head of Business Development for GlaxoSmithKline (GSK) Rare Diseases where he was responsible for partnerships, licensing and mergers and acquisitions (M&A). Earlier in his career at GSK, Mike was a partner in its corporate venture capital firm, SR One, Limited where he was responsible for many of the firm’s investments and served on the boards of numerous companies. Prior to GSK, Mike was an associate at Frantz Medical Ventures and practiced medicine for 6 years.

Dr. Diem holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School, an MBA from the Weatherhead School of Management at Case Western Reserve University, completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program.

About VenatoRx Pharmaceuticals, Inc.

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of the next generation of antibiotics. VenatoRx focuses on immediate and emerging threats, including both serious hospital and community infections, as well as potential bioweapons agents. The Company’s research and development include programs for novel beta-lactamase inhibitors, penicillin binding protein inhibitors, next generation carbapenems, and antiviral agents. The Company’s lead program, a pan-beta-lactamase inhibitor, is being developed through an NIH contract and by a Wellcome Trust Foundation Translational Fund Award. The Company has also received numerous NIH grants that support the Company’s research and development programs.

READ FULL TEXT